Issue 100, 2019

A lipase-responsive antifungal nanoplatform for synergistic photodynamic/photothermal/pharmaco-therapy of azole-resistant Candida albicans infections

Abstract

A lipase-triggered drug release nanoplatform (PGL-DPP–FLU NPs) for multi-modal antifungal therapy is developed. The lipases secreted by C. albicans can accelerate FLU release. The ROS and heat produced by PGL-DPP–FLU NPs make C. albicans more vulnerable to FLU, thereby PGL-DPP–FLU NPs exhibit high performance for combating azole-resistant C. albicans biofilms and wound infection.

Graphical abstract: A lipase-responsive antifungal nanoplatform for synergistic photodynamic/photothermal/pharmaco-therapy of azole-resistant Candida albicans infections

Supplementary files

Article information

Article type
Communication
Submitted
30 Oct 2019
Accepted
25 Nov 2019
First published
25 Nov 2019

Chem. Commun., 2019,55, 15145-15148

A lipase-responsive antifungal nanoplatform for synergistic photodynamic/photothermal/pharmaco-therapy of azole-resistant Candida albicans infections

D. Yang, X. Lv, L. Xue, N. Yang, Y. Hu, L. Weng, N. Fu, L. Wang and X. Dong, Chem. Commun., 2019, 55, 15145 DOI: 10.1039/C9CC08463K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements